Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Substituted heterocylic compounds

a heterocyclic compound and substitute technology, applied in the field of substitution of heterocyclic compounds, can solve problems such as ineffective treatment of these conditions

Inactive Publication Date: 2013-11-07
INCYTE CORP
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention provides new compounds (Formula I and XI) that can be used for treating histamine H4 receptor-related conditions, diseases, and disorders. These compounds have been found to have activity in modulating the activity of this receptor, inhibiting its activity, or treating such conditions associated with it. The invention also provides pharmaceutical compositions and methods for using these compounds in therapy.

Problems solved by technology

For examples, histamine is known to be involved in asthma and in the pruritus associated with atopic dermatitis and chronic idiopathic urticaria, but current anti-H1 and anti-H2 compounds (antagonists of H1 and / or H2 receptor), which are not active against H4 receptor (Thurmond et al., Nature Review Drug Discovery, 7:41-53, 2008), are ineffective in treating these conditions.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Substituted heterocylic compounds
  • Substituted heterocylic compounds
  • Substituted heterocylic compounds

Examples

Experimental program
Comparison scheme
Effect test

example 1

4-(4-Methylpiperazin-1-yl)-6-(1,2,3,4-tetrahydroisoquinolin-7-yl)pyrimidin-2-amine

[0595]

Step 1: tert-butyl 7-bromo-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0596]

[0597]Di-tert-butyldicarbonate (0.34 g, 1.6 mmol) was added to a mixture of 7-bromo-1,2,3,4-tetrahydroisoquinoline (0.30 g, 1.4 mmol, Alfa Aesar, Cat. #: B25712) and triethylamine (0.29 g, 2.8 mmol) in THF (4.0 mL). The mixture was stirred at room temperature (r.t.) for 1 hour (1 h.), quenched with aqueous Na2CO3, and extracted with ethyl acetate (3×20 mL). The combined organic layers were washed with brine, dried over MgSO4, filtered, and concentrated under reduced pressure to afford the desired product (0.43 g, yield: 97%) which was directly used in next step reaction without further purification. Analytic LCMS (M+Na)+: m / z=334.2 / 336.2; (M-But+H)+=256.1 / 258.1.

Step 2: tert-butyl 7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinoline-2(1H)-carboxylate

[0598]

[0599]To a solution of tert-butyl 7-bromo-3,4-dihyd...

example 2

4-[2-(4-Chlorobenzoyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]-6-(4-methylpiperazin-1-yl)pyrimidin-2-amine

[0604]

[0605]4-Chlorobenzoic acid chloride (4.4 μL, 0.034 mmol) was added to a mixture of 4-(4-methylpiperazin-1-yl)-6-(1,2,3,4-tetrahydroisoquinolin-7-yl)pyrimidin-2-amine HCl salt (10 mg, 0.02 mmol) and triethylamine (16 μL, 0.12 mmol) in tetrahydrofuran (0.3 mL). After 30 min, the mixture was purified by RP-LCMS (pH=10) to afford the desired products. Analytic LCMS (M+H)+: m / z=463.3 / 465.3

example 3

4-[2-(Cyclobutylcarbonyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]-6-(4-methylpiperazin-1-yl)pyrimidin-2-amine

[0606]

[0607]This compound was prepared from cyclobutanecarboxylic acid chloride and 4-(4-methylpiperazin-1-yl)-6-(1,2,3,4-tetrahydroisoquinolin-7-yl)pyrimidin-2-amine HCl salt using procedures analogous to those for Example 2. Analytic LCMS (M+H)+: m / z=407.4.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to substituted heterocyclic compounds of Formula I or XI:or pharmaceutically acceptable salts or N-oxides or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are histamine H4 receptor inhibitors useful in the treatment of histamine H4 receptor-associated conditions or diseases or disorders including, for example, inflammatory diseases or disorders, pruritus, and pain.

Description

[0001]This application claims benefit of priority to U.S. provisional patent application Ser. No. 61 / 161,939 filed on Mar. 20, 2009, which is hereby incorporated by reference in its entirety.FIELD OF THE INVENTION[0002]The present invention relates to substituted heterocyclic compounds, and compositions thereof as well as methods of use the same for treatment of histamine H4 receptor associated conditions or diseases or disorders such as inflammatory disorders, pruritus, and pain.BACKGROUND OF THE INVENTION[0003]Histamine is a biogenic amine that exerts its physiological and pathological functions through four G-protein coupled receptors, histamine receptors H1, H2, H3, and H4 (Parsons and Ganellin, Br. J. Pharm., 147:S127-S135, 2006). The roles of the first three receptors in mediating histamine functions have been well characterized: histamine mediates acute allergic responses via histamine H1 receptor (A. S. F. Ash and H. O. Schild, Br. J. Pharmac. Chemother., 27:427-439, 1966), ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07D401/06A61K45/06C07D239/95A61K31/506C07D403/12C07D409/12C07D405/12C07D401/14A61K31/517C07D417/12
CPCC07D401/06A61K31/517A61K45/06C07D239/95C07D417/12C07D403/12C07D409/12C07D405/12C07D401/14A61K31/506C07D239/48C07D239/84A61P11/02A61P11/06A61P17/00A61P17/02A61P17/04A61P19/02A61P29/00A61P37/08
Inventor ZHUO, JINCONGMADUSKUIE, THOMAS P.QIAN, DING-QUANYAO, WENQING
Owner INCYTE CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com